Previous 10 | Next 10 |
ChromaDex ( NASDAQ: CDXC ) has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023. Gerber served as Senior Vice President, Finance / Interim CFO of ChromaDex since August 11, 2022. Prior to that was the Vice President of Finance and Inve...
ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it has appointed Brianna Gerber to the role of Chief Financial Officer, effective January 1, 2023. Gerber served as Senior Vice President, Finance / Interim Chief Financial Officer of ChromaDex s...
Results from this study on healthy subjects support previous research demonstrating that NR supplementation may impact neurodegenerative biomarkers commonly associated with aging ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising n...
Summary Shares of dietary supplement concern ChromaDex are down more than 80% since February 2021 as sales momentum for its flagship Tru Niagen product has stalled. The company’s 2Q21 3,800-plus location launch in Walmart was truncated to 2,000 stores as brand awareness has...
U.S. FDA declares NMN ingredient may not be sold or marketed as a dietary supplement in the U.S. since first investigated as a drug ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that on November 4, 2022, the U.S. FDA d...
ChromaDex Corporation (CDXC) Q3 2022 Earnings Conference Call November 2, 2022 16:30 ET Company Participants Tom Shumaker - Investor Relations Robert Fried - Chief Executive Officer Brianna Gerber - Interim Chief Financial Officer Conference Call Participan...
ChromaDex press release ( NASDAQ: CDXC ): Q3 Non-GAAP EPS of -$0.04 beats by $0.02 . Revenue of $17.06M (-1.4% Y/Y) misses by $1.68M . Adjusted EBITDA including total legal expense, a non-GAAP measure, was a loss of $1.2 million, a $5.1 million improvement from...
Total net sales of $17.1 million, with gross margin of 59.8%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.0 million and $1.2 million, respectively, for the three months ended September 30, 2022. ChromaDex Corp. (NASDAQ:CDXC) today announced f...
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 2, 2022 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended Septe...
Tru Niagen ® was recognized for its industry-leading research, increased presence on cross-border e-commerce channels, and high engagement on several social media platforms in Mainland China ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicate...
News, Short Squeeze, Breakout and More Instantly...
ChromaDex Corporation Company Name:
CDXC Stock Symbol:
NASDAQ Market:
ChromaDex Corporation Website:
U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper...
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen ® supplement, backed by strong financial performance and a robust intellectual property portfolio ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD +...
NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD + ) research, shares results from a milestone phase II clinical study showcasing the promising effe...